Search

everythinglearnresearchcommunity

for

Search:↓

Guselkumab significantly improves quality of life for people with moderate to severe psoriasis.

Pemphigus vulgaris involves specific immune cells and B cells that produce antibodies causing skin blisters.

IMG-007 helps regrow hair and reduce scalp inflammation in severe alopecia areata.

Rituximab improved her dermatomyositis better than usual treatments.

Tebentafusp-tebn improves survival rates in uveal melanoma patients but has common side effects like rash and fatigue.

A patient got a skin reaction on their hands and feet after using secukinumab for psoriasis.

Combining mesotherapy with systemic treatments effectively improves alopecia universalis treatment.

BAFF-targeted therapies can reduce autoimmune disease activity, but more research is needed for precise treatments.

Methylprednisolone helps skin cells stick together better in pemphigus vulgaris.

Bimatoprost shows promise for treating vitiligo, especially when combined with other therapies.

Bortezomib chemotherapy can cause temporary skin rashes.

A combination of ixekizumab and tofacitinib successfully treated severe scalp cellulitis, leading to hair regrowth.

Baricitinib is effective and cost-efficient for treating severe alopecia areata in adults.

Oral tofacitinib shows promise in treating atopic dermatitis and alopecia areata, but only slight improvement in vitiligo.

Immunosuppressive and anti-TNF therapies in IBD patients can increase the risk of skin cancer and cause various skin issues.

JAK inhibitors are more effective and safer for treating alopecia areata than dupilumab and apremilast.

A woman with alopecia regrew her hair after taking a higher dose of tocilizumab.

Tralokinumab effectively improved atopic dermatitis symptoms in most patients, but some stopped due to side effects like hair loss.

An 18-year-old girl with pemphigus vulgaris needed strong medication and careful treatment due to ineffective initial therapies and side effects.

Guselkumab significantly improves psoriasis symptoms within 12 weeks.

Pembrolizumab can cause serious liver issues, requiring close monitoring and early treatment.

Adding dupilumab led to almost complete hair regrowth in a patient with alopecia areata who only partially responded to baricitinib.

BKN-1 antibody targets specific keratin in basal cell epithelioma and normal skin basal cells.

A woman with severe angioedema improved significantly after treatment with rituximab.

A woman with a drug allergy to anakinra was successfully desensitized, allowing her to continue treatment without allergic reactions.

Mesotherapy with bicalutamide has limited effectiveness for female hair loss.

Pembrolizumab can cause unusual eyelash growth, but it may still be worth continuing if cancer treatment is effective.

Dual-targeting therapies like Janus kinase inhibitors may treat both alopecia areata and other immune diseases.

Imiquimod improved skin pigmentation in most patients with xeroderma pigmentosum and may prevent further skin cancer, but some treatments can have side effects.

Secukinumab treatment may cause HBV reactivation and hair discoloration.